The analyst confirms his buy recommendation on the share, with an unchanged target price of 2040 pence, representing a potential upside of 20%.

' GSK's first-quarter results exceeded expectations, leading to a slight increase in full-year forecasts. We consider the valuation to be low given the growth outlook and are monitoring progress on Zantac and important catalysts' says UBS.

' UBS expects sales growth of 4% and EPS growth of 6% for fiscal 2024. UBS's forecasts are 2% below the recent consensus provided by the company' says the analyst firm.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.